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Introduction
Exposure to asbestos fibers increases the risk of disease 
and death for different causes, but its impact on health is 
not properly reflected in statistics on occupational disease 
and must be quantified in specific studies. There have been 
some local studies of this type1) and in relation to specific 
diseases in Spain2, 3), but none in which all asbestos-related 
diseases (ARDs) were considered.
Exposure to asbestos has specific pathological effects, 
including asbestosis, the formation of pleural plaques on 
the parietal pleura with or without calcification, visceral 
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pleura thickening; benign pleural effusion, and malignant 
mesothelioma (involving pleura, peritoneum, pericardium, 
and tunica vaginalis of the testes)4). Exposure can also 
increase the risk of other cancers, notably lung cancer5). 
In 2012, the International Agency for Research on Cancer 
added the larynx and ovaries as two further cancer sites 
related to asbestos exposure6). In addition, positive asso-
ciations have been observed between exposure to all forms 
of asbestos and cancer of the pharynx, stomach, and col-
orectum6).
The WHO has estimated that more than 107,000 peo-
ple die annually from asbestos-related mesothelioma, 
lung cancer and asbestosis7). In Spain, 2,514,346 tons of 
asbestos were imported between 1906 and 2001, the year 
in which the utilization, production, and sale of asbestos 
fibers and associated products were prohibited8). A large 
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proportion of the imported asbestos was used in buildings, 
pipes, and roofs constructed between the 1960s and 1990s; 
hence, the mortality and morbidity burden due to asbes-
tos exposure will continue to rise over the next few years, 
given the usually long latency period before the appear-
ance of these diseases (e.g., up to 40–50 years for meso-
thelioma)9).
An account was recently published of the asbestos-
related occupational diseases recognized by the Spanish 
National Insurance System between 1961 (when asbes-
tosis was first acknowledged as an occupational disease) 
and 2010, recording 815 cases of asbestosis10). In addition, 
164 asbestos-related occupational cancers were recorded 
between 1978, when asbestos-related bronchopulmonary 
cancers and mesothelioma were first recognized as occu-
pational diseases, and 201111). These data contrast with the 
more conservative estimates published in other studies, 
suggesting that an accurate picture of the true impact of 
asbestos on health requires the integration of information 
on patients with asbestosis, pleural plaques, or mesothelio-
mas treated in the Spanish National Health Service (NHS) 
and on the population-attributable fraction of tumors 
known to be associated with asbestos exposure, i.e., in 
lung, larynx, ovary, colon, and rectum6).
The medical costs of treating ARDs have received little 
attention. The objective of this study was to estimate the 
burden of malignant ARDs to the Spanish NHS between 
2004 and 2011, calculating the direct medical costs of its 
treatment. Estimation of the burden of a disease and its 
costs is essential for taking optimal public health decisions 
in relation to risk reduction/control measures and the plan-
ning of human and material healthcare resources.
Methods
The burden (number) of ARDs in Spain between 2004 
and 2011 was estimated by identifying all cases due to 
asbestosis, almost all cases due to mesothelioma, and the 
proportion (and therefore number) of cases of lung, laryn-
geal, ovarian, colon and rectum cancers attributable to 
asbestos exposure. Table 1 provides a matrix of disease 
categories [with International Classification of Diseases-
9th Revision (ICD-9) codes] and the population-attribut-
able fraction by sex12–15). These data were combined with 
healthcare and associated costs obtained from the different 
NHS care levels. A prevalence approach was used to esti-
mate the overall burden of ARDs. The study period begins 
in 2004, the first year with available data on specialist out-
patient care, and ends in 2011, the latest year for which 
data are available on each disease type.
Mesotheliomas as a proportion of recorded pleural and 
peritoneal cancers
The Spanish NHS uses the ICD-9 classification system, 
which has no specific code for mesothelioma. Therefore, 
we applied a multiplier obtained in a previous study on the 
proportion of pleural and peritoneal cancers estimated to 
be mesotheliomas in Spain between 2004 and 20069), in 
which 362 out of 496 deaths coded as cancer of the pleura 
were pleural mesotheliomas, and 51 out of 673 coded as 
cancer of the peritoneum were peritoneal mesotheliomas. 
Hence, the number of cases due to pleural mesothelioma 
was estimated by multiplying the number of pleural cancer 
cases by 0.68 (0.73 in men and 0.55 in women), and the 
number due to peritoneal mesothelioma was estimated by 
multiplying the number of peritoneal cancer cases by 0.08 
(0.1 in men and 0.05 in women).
Calculation of the costs
We estimated direct healthcare costs of ARD’s for the 
Spanish NHS. Two types of analysis were performed: a) 
using NHS data on the cost of specialist (hospital and out-
patient) care to compute the cost of cases treated at NHS 
hospitals; and b) mining secondary data sources to estimate 
Table 1. Matrix of diseases, ICD codes, and attributable fractions due to occupational asbestos exposure by sex
DISEASE CIE-9 CIE-10
Attributable fraction (%)
(95% Confidence interval) SOURCE
Males Females Total
Asbestosis 501 J61 100 100 100 WHO12)
Mesothelioma 158, 163 C45  97(96.0–98.0)
82.5
(75.0–90.0)
94.9
(93.0–96.9) Rushton et al.
13)
Lung 162 C33-C34  14 0.6 — Nurminen, Karjalainen14)
Laryngeal 161 C32 8.3 0.3 — Nurminen, Karjalainen14)
Ovarian 183.0 C56 — 0.2–0.5 0.3 Driscoll15)
Colon 153 C18 2.3 0 — Nurminen, Karjalainen14)
Rectum 154 C20 2.9 0 — Nurminen, Karjalainen14)
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the costs of primary healthcare and prescription drugsa.
Data in the Information System of the NHS was accessed 
using the NHS Interactive Consultation program, selecting 
the registry of hospital discharges (CMBD-H) and registry 
of specialist outpatient care (CMBD-AAE)16). The study 
variables and inclusion criteria were as follows:
— Years: from 2004 through 2011;
— Age and sex: males or females aged 25 years or 
older for asbestosis, 40 years or older for mesothelio-
mas, and 25 years or older for other asbestos-related 
cancers;
— Diagnosis: main diagnosis coded using the ICD-9 
system (5 digits);
— Subjects in the CMBD-H database: patients dis-
charged from a Spanish public hospital, excluding 
those with discharge date unavailable or outside the 
study period, those with admission and discharge 
on the same day (non-hospitalized), and discarding 
duplicate records;
— Subjects in the CMBD-AAE database: patients 
receiving specialist outpatient care (sessions, visits, 
contacts) in day hospital, outpatient department, or at 
home, excluding those with discharge date unavail-
able or outside the study period and discarding dupli-
cate records;
— Mean length of hospital stay;
— Cost: mean estimated cost of treating these patients 
in a representative sample of NHS hospitals for each 
year studied;
— Weighted Activity Unit (WAU): the unit cost of spe-
cialist outpatient care in the years under study, based 
on the official measure WAU (known in Spain as the 
unidad ponderada asistencial UPA)17, 18).
Estimations of primary healthcare and pharmaceutical 
costs were based on data from a Catalonian health district 
(Baix Empordà) for 2004, 2005, 2006, 2007 and 2011, the 
years for which cost data were available by clinical risk 
group. We calculated the costs for primary care and phar-
maceutical care as a proportion of costs for specialist care. 
Primary care included the total use of primary healthcare 
resources (family doctor, nursing staff or emergencies), 
pharmaceutical care included all expenditure on prescrip-
tion drugs, and specialist care included inpatient care, spe-
cialist outpatient care and also the hospital pharmaceutical 
costs, which are included in the CMBD and WAU data-
bases. Information on costs related to long-stay hospitals 
was not considered because these data are not included in 
the CMBD database.
Because the Baix Empordà district covers a relatively 
small population (around 134,000 in 2013), only a small 
number of patients were recorded in each diagnostic 
group under study. It would therefore have been inappro-
priate to calculate the mean cost of each disease per year, 
which may be heavily influenced by the severity of a given 
patient. For this reason, we computed the mean cost of 
each disease over the entire study period and for the whole 
population (males and females). The ratios obtained were 
applied to the time-series data on specialist care costs in 
order to obtain the primary care and pharmaceutical care 
expenditure.
Table 2 exhibits these calculations, in which the ‘cost 
factor for primary care’ is the primary care expenditure 
divided by the specialist care expenditure, and the ‘cost 
factor for pharmaceutical care’ is the pharmaceutical care 
expenditure divided by the specialist care expenditure.
The cost factors for primary care and pharmaceutical 
care were not available for asbestosis or mesothelioma, 
because there were no records of patients with these dis-
a We are very grateful to Jose M. Inoriza and Marc Carreras from Serveis de Salut Integrats Baix Empordà, who provided us the data, for 
their valuable assistance.
Table 2. Distribution of number of patients and public healthcare budget across disease categories and types of 
service in Baix Empordà (euros) and cost factors (relative weights) for primary healthcare and pharmaceutical care
LUNG LARYNX OVARY COLON/RECTUM
n Mean cost n Mean cost n Mean cost n Mean cost
Primary Care 349   345.8 461   345.8 87   322.3 495   259.9
Pharmaceutical Care 349 1,302.6 461 1,302.6 87   710.5 495 1,418.5
Specialized Care 349 1,652.2 461 1,652.2 87 1,777.6 495 1,826.7
Cost factor for PC (PC/SC) 0.21 0.22 0.18 0.14
Cost factor for PhC (PhC/SC) 0.79 0.60 0.40 0.78
PC=primary care, SC=specialist care, PhC=pharmaceutical care
Source: prepared by the authors from primary data provided by Serveis de Salut Integrats Baix Empordà.
M GARCÍA-GÓMEZ et al.6
Industrial Health 2017, 55, 3–12
eases in Baix Empordà during the analyzed period. There-
fore, the cost factor obtained for lung cancer was used 
for these diseases, on the grounds that their medical costs 
would be relatively similar.
Results
Between 2004 and 2011, there were 37,557 admissions 
for ARDs to Spanish public hospitals of individuals over 
the age of 25 years ( > 40 years in the case of mesotheli-
oma), 97.1% of whom were male and 2.9% female. The 
rate of hospital discharges for ARDs per 100,000 Social 
Security-affiliated employees was 43.9 in males and 1.9 
in females. Over this period, men showed a slight increase 
in this rate (43.9 in 2004 vs. 49.2 in 2011), while women 
evidenced stability (1.8 in 2004 vs. 1.9 in 2011). Hospital 
admissions for mesothelioma increased, especially among 
males (350 occupational-related cases in 2004 vs. 449 in 
2011), while admissions for asbestosis decreased (39 in 
2004 vs. 31 in 2011) (Table 3).
Table 3. Hospital cost per asbestos-related disease by sex. Spain 2004–2011
Asbestos-related 
disease
(ARD)
Number of hospital 
discharges
Mean length 
of stay
(days)
Cost per process
(in euros)
Cases 
attributable to 
occupational 
exposure
Hospital cost per ARD
(in euros)
M F M F M F M F M F
Asbestosis
2004 36 3 11.92 5.33 4,093.89 3,434.31 36 3 147,379.94 10,302.92
2011 28 3 8.61 12 4,128.48 6,344.86 28 3 115,597.45 19,034.57
2004–2011 268 21 9.87 7.48 4,110.27 4,290.10 268 21 1,101,552.15 90,091.99
Mesothelioma
2004 361 107 14.24 13.97 5,832.20 5,907.79 350 88 2,041,270.00 519,885.52
2011 463 123 11.25 12.13 8,093.18 8,481.00 449 102 3,633,837.82 865,062.00
2004–2011 3,165 960 12.96 13.94 6,815.73 7,228.29 3,07 791 20,924,690.93 5,719,074.03
Malignant neoplasm of trachea, bronchus and lung
2004 23,041 3,060 11.78 12.40 5,092.20 5,072.77 3,226 18 16,427,451.14 91,309.94
2011 22,868 4,776 9.92 10.13 5,621.33 5,405.07 3,202 29 17,999,483.46 156,747.17
2004–2011 182,476 30,527 11.13 11.39 5,411.89 5,436.92 25,547 183 138,257,940.44 995,173.44
Malignant neoplasm of larynx
2004 5,152 263 15.07 14.20 7,056.81 6,753.14 428 1 3,020,313.5 6,753.14
2011 4,742 323 12.84 12.76 8,704.33 8,864.76 394 1 3,429,504.72 8,864.76
2004–2011 39,936 2,234 14.46 13.56 8,329.03 8,318.36 3,314 8 27,601,055.38 66,140.42
Malignant neoplasm of ovary
2004 — 3,704 — 13.22 — 5,506.38 — 11 — 60,570.14
2011 — 4,046 — 10.74 — 8,077.14 — 12 — 96,925.73
2004–2011 — 31,191 — 12.12 — 6,313.99 — 93 — 586,988.37
Malignant neoplasm of colon
2004 10,765 7,843 16.79 16.68 7,614.87 7,209.04 248 0 1,888,488.06 0
2011 14,519 10,029 13.75 13.06 10,932.31 10,125.43 334 0 3,651,392.64 0
2004–2011 100,491 72,381 15.37 14.92 9,490.83 8,840.00 2,311 0 21,933,092.35 0
Malignant neoplasm of rectum
2004 7,715 4,504 16.51 16.55 6,831.67 6,594.42 224 0 1,530,293.27 0
2011 8,868 4,949 13.73 13.17 10,030.18 9,441.17 257 0 2,577,757.24 0
2004–2011 67,270 38,205 15.54 14.93 8,651.76 8,158.30 1,951 0 16,877,571.21 0
Total ARD
2004 47,070 15,780 14.08 18.85 6,174.19 7,894.71 4,512 121 25,055,195.91 688,821.66
2011 51,488 20,203 11.94 14.53 8,183.68 10,428.77 4,664 147 31,407,573.33 1,146,634.23
2004–2011 393,606 144,328 13.32 16.77 7,313.38 9,284.83 36,461 1,096 226,695,902.46 7,457,468.25
Source: prepared by the authors from data provided by the National Health System “Consulta Interactiva”, Ministerio de Sanidad, Servicios 
Sociales e Igualdad. Instituto de Información Sanitaria (2013)16)
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Between 2004 and 2011 there were 5,253 specialist out-
patient visits for the diseases under study, 97.4% by men 
and 2.6% by women (Table 4). Although the male-female 
ratio differed among the diseases, there was always a pre-
dominance of males. Cases attended in day hospitals were 
6-fold higher in 2011 than in 2004, with a 14-fold increase 
for females, and an increase was observed in both sexes for 
all diseases under study with the exception of asbestosis.
Hospital cost per disease was highest for colon and 
rectum cancers, which also required a longer hospital 
stay. The mean length of hospital stay tended to decrease 
over the study period for all diseases in both sexes except 
for asbestosis in women. The lowest hospital costs were 
for asbestosis. The cost was higher in women for meso-
thelioma (Table 3). The total public hospital cost for the 
eight-year study period was 234,153,370.71 €, of which 
96.8% corresponded to male patients. Between 2004 and 
2011, these costs rose by 25.3% for men and by 66.5% 
for women. The total cost of specialist outpatient care for 
these diseases was 2,045,543.95 € over the same period 
Table 4. Cost of specialized outpatient care per asbestos-related disease by sex. Spain 2004–2011
Asbestos-related 
disease
(ARD)
Number of 
consultations 
in specialist 
outpatient care
Weighted activity 
unit cost
(in euros)
Specialist outpatient 
care consultations 
attributable to 
occupational exposure
Specialist outpatient care 
cost per ARD
(in euros)
M F M F M F M F
Asbestosis
2004 0 0 0 0 0 0 0 0
2011 2 0 359.74 0 2 0 719.49 0
2004–2011 15 4 308.61 481.36 15 4 4,629.20 1,925.43
Mesothelioma
2004 5 2 295.85 299.52 5 1 1,479.23 299.52
2011 62 35 472.20 416.07 60 28 28,331.96 11,649.87
2004–2011 196 93 396.28 369.59 191 75 75,595.26 27,703.06
Malignant neoplasm of trachea, bronchus and lung
2004 852 190 324.25 306.87 119 1 38,585.41 306.87
2011 4,507 1,399 424.91 400.20 631 8 268,117.36 3,201.62
2004–2011 22,765 5,438 379.94 373.61 3,188 33 1,211,236.48 12,325.12
Malignant neoplasm of larynx
2004 363 23 351.23 356.74 30 0 10,536.81 0
2011 1,175 68 508.62 520.86 98 0 49,844.41 0
2004–2011 5,990 370 454.05 494.74 498 0 226,139.29 0
Malignant neoplasm of ovary
2004 — 393 — 312.45 — 1 — 312.45
2011 — 1,516 — 564.20 — 5 — 2,821.01
2004–2011 — 7,290 — 426.55 — 22 — 9,548.98
Malignant neoplasm of colon
2004 545 389 340.18 324.10 13 0 4,422.40 0
2011 6,046 3,697 596.40 552.38 139 0 47,285.68 0
2004–2011 30,599 19,699 499.10 464.88 705 0 239,830.24 0
Malignant neoplasm of rectum
2004 289 202 310.37 298.78 8 0 2,482.95 0
2011 3,433 1,865 548.04 515.86 100 0 54,804.48 0
2004–2011 17,947 10,121 453.21 449.67 522 0 236,610.88 0
Total ARD
2004 2,054 1,199 331.22 313.87 175 3 57,506.80 918.84
2011 15,225 8,580 527.42 375.36 1,030 41 449,103.38 17,672.5
2004–2011 77,512 43,015 449.70 344.78 5,119 134 1,994,041.35 51,502.59
Source: prepared by the authors from data provided by the National Health System “Consulta Interactiva”, Ministerio de 
Sanidad, Servicios Sociales e Igualdad. Instituto de Información Sanitaria (2013)16)
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(Table 4) and evidenced the greatest rise in costs between 
2004 and 2011, with a 19.2-fold increase in females and 
7.8-fold increase in males. Globally, the total cost of spe-
cialist healthcare (hospital+outpatient) was 236,198,914.7 
€.
Table 5 displays the annual costs of healthcare services 
and prescriptions for the seven ARDs studied between 
2004 and 2011. The total cost over the 8-year period was 
463,983,511 €, being 30.4-fold higher for male vs. female 
cases. This total cost began to rise after 2006, increasing by 
27.8% between 2004 and 2011 (26.7% for males vs. 68.9% 
for females). This increase was not uniform over the period 
and even decreased slightly in 2005 and 2010. Among the 
years showing an inter-annual increase, this ranged from 
2.5% between 2008 and 2009 to 8.9% between 2006 and 
2007. The only ARD evidencing a reduction in total costs 
over the study period was asbestosis in men. These inter-
annual changes were relatively similar among the three 
types of healthcare considered. The highest costs incurred 
over the period were for tracheal and bronchopulmo-
nary cancers, both globally (60.5%) and among the men 
(62.1%), whereas mesothelioma incurred the highest costs 
among the women (77.9% of total for females). Specialist 
healthcare represented 50.9% of the total healthcare cost 
of these ARDs. The next highest cost was that for pharma-
ceutical care, which represented 38.95% of the total, while 
Table 5. Total healthcare cost per asbestos-related disease by type of service and sex (euros). Spain 2004–2011
Asbestos-related 
disease
(ARD)
Specialist care cost Primary care cost Pharmaceutical care cost Healthcare cost per ARD
M F M F M F M F
Asbestosis
2004 147,379.94 10,302.92 30,949.79 2,163.61 116,430.15 8,139.31 294,759.88 20,605.84
2011 116,316.93 19,034.57 24,426.56 3,997.26 91,890.37 15,037.31 232,633.86 38,069.14
2004–2011 1,106,181.35 92,017.41 232,298.08 19,323.66 873,883.27 72,693.75 2,212,362.70 184,034.82
Mesothelioma
2004 2,042,748.22 520,184.67 428,977.13 109,238.78 1,613,771.09 410,945.89 4,085,496.44 1,040,369.34
2011 3,662,168.71 876,712.17 769,055.43 184,109.56 2,893,113.28 692,602.61 7,324,337.42 1,753,424.34
2004–2011 21,000,285.21 5,746,776.18 4,410,059.89 1,206,822.00 16,590,225.32 4,539,953.18 42,000,570.42 11,493,552.36
Malignant neoplasm of trachea bronchus, and lung
2004 16,466,036.55 91,616.81 3,457,867.68 19,239.53 13,008,168.87 72,377.28 32,932,073.10 183,233.62
2011 18,267,600.82 159,948.79 3,836,196.17 33,589.25 14,431,404.65 126,359.54 36,535,201.64 319,897.58
2004–2011 139,469,176.91 1,007,498.57 29,288,527.15 211,574.70 110,180,649.76 795,923.87 278,938,353.82 2,014,997.14
Malignant neoplasm of larynx
2004 3,030,850.31 6,753.14 666,787.07 1,485.69 1,818,510.19 4,051.88 5,516,147.56 12,290.71
2011 3,479,349.13 8,864.76 765,456.81 1,950.25 2,087,609.48 5,318.86 6,332,415.42 16,133.86
2004–2011 27,827,194.66 66,140.42 6,121,982.83 14,550.89 16,696,316.80 39,684.25 50,645,494.28 120,375.56
Malignant neoplasm of ovary
2004 — 60,882.59 — 10,958.87 — 24,353.04 — 96,194.49
2011 — 99,746.74 — 17,954.41 — 39,898.70 — 157,599.85
2004–2011 — 596,537.34 — 107,376.72 — 238,614.94 — 942,528.00
Malignant neoplasm of colon
2004 1,892,910.46 0 265,007.46 0 1,476,470.16 0 3,634,388.08 0
2011 3,698,678.31 0 517,814.96 0 2,884,969.08 0 7,101,462.36 0
2004–2011 22,172,922.58 0 3,104,209.16 0 17,294,879.61 0 42,572,011.35 0
Malignant neoplasm of rectum
2004 1,532,776.22 0 214,588.67 0 1,195,565.45 0 2,942,930.34 0
2011 2,632,561.72 0 368,558.64 0 2,053,398.14 0 5,054,518.50 0
2004–2011 17,114,182.11 0 2,395,985.50 0 13,349,062.05 0 32,859,229.65 0
Total ARD
2004 25,112,701.70 689,740.13 5,064,177.79 143,086.48 19,228,915.92 519,867.40 49,405,795.41 1,352,694.01
2011 31,856,675.62 1,164,307.03 6,281,508.57 241,600.72 24,442,385.00 879,217.02 62,580,569.19 2,285,124.77
2004–2011 228,689,942.82 7,508,969.92 45,553,062.61 1,559,648.97 174,985,016.80 5,686,869.99 449,228,022.23 14,755,488.88
Source: prepared by the authors from Tables 1–4.
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primary healthcare was responsible for 10.15% of the total 
costs.
Finally, Table 6 lists the mean costs per case for each 
ARD in 2004 and 2011 and in the whole period under 
study (2004–2011) as well as the mean age (SD) of hos-
pital inpatients, the only patients for whom these data are 
available.
Discussion and Conclusion
The historic use and handling of asbestos in Spain con-
tinue to evidence a major impact on health. ARDs produce 
around 4,700 hospital admissions and over 650 specialist 
outpatient consultancies per year, and their direct annual 
cost to the Spanish NHS is estimated to be around 58 mil-
lion euros. In fact, this is an underestimation of the global 
expenditure by the NHS on ARDs, given that the fraction 
of pharynx and stomach cancers attributable to asbestos 
has not been considered. In industrialized countries, occu-
pational exposure is responsible for 100% of asbestosis 
cases, at least 85% of mesothelioma cases, and a variable 
proportion of the other diseases studied. Between 2004 and 
2011, 37,557 public hospital admissions were for ARDs in 
individuals aged 25 years or more ( > 40 yrs for cases of 
mesothelioma), mainly for lung cancer, mesothelioma, or 
laryngeal cancer. Furthermore, 2,611 individuals aged 40 
years or older (1,952 men and 659 women) died from pleu-
ral mesothelioma over the eight-year study period16). In 
contrast, only 490 cases of ARDs were recognized as occu-
pational diseases under the Spanish National Insurance 
System over the same period: 81 cases of mesotheliomas, 
66 of bronchopulmonary cancer, 280 of asbestosis, and 63 
of pleural plaques10,11). Evaluating the costs of ARDs based 
on workers’ compensation can lead to gross underestima-
tions and hinder comparison between countries, because 
of differences in national legislative frameworks, insur-
ance systems, and recognition rates. Thus, compensation 
schemes cover 35% of mesothelioma cases in Italy and 
between 16% and 25% of those in France, depending on 
the region19), whereas only 6.4% of mesothelioma cases in 
men and 0.3% of those in women are considered as occu-
pational diseases in Spain11). The gross under-recognition 
of ARDs in Spain not only reveals the deficiencies of the 
Spanish National Insurance System but also has a negative 
economic impact on the NHS, which is estimated to incur 
healthcare costs of 58 million euros every year that should 
be paid under the compensation scheme for occupational 
ARDs victims. It is estimated that over a thousand individ-
uals will die from pleural mesothelioma in Spain between 
2016 and 2020, and asbestos-related deaths are expected to 
continue until at least 20409). For this reason, the gather-
ing, analysis, and diffusion of data on these diseases and 
on their relationship with occupational exposure is crucial 
for planning prevention and healthcare programs and for 
the appropriate compensation of victims. The calculations 
and analysis of the healthcare burden of ARDs in our study 
represent useful tools for informing decisions and redefin-
ing health policies and the human and material resources 
required.
More than half (68.5%) of hospital admissions for 
ARDs were for bronchopulmonary cancers, followed by 
mesothelioma (10.3%) and laryngeal cancer (8.8%), while 
the smallest number was for asbestosis (0.8%), similar to 
previous findings in Europe20). We highlight the marked 
Table 6. Mean age (SD) and mean healthcare cost per asbestos-
related disease by sex (euros). Spain 2004–2011
Asbestos-
related disease 
(ARD)
Mean age (SD)
Mean healthcare cost 
per ARD (in euros)
M F M F
Asbestosis
2004 72.8 (7.4) 80.3 (2.9) 8,187.77 6,868.61
2011 73 (10.2) 73.6 (10.4) 8,308.35 12,689.71
2004–2011 72.6 (8.9) 74.3 (13.1) 8,307.78 9,057.85
Mesothelioma
2004 67.5 (10.7) 67.2 (13.2) 11,672.85 11,822.38
2011 69.4 (10.6) 69.1 (11.6) 16,312.56 17,190.43
2004–2011 68.6 (10.3) 68.9 (12.1) 13,571.92 14,444.55
Malignant neoplasm of trachea, bronchus, and lung
2004 66.2 (11) 62.5 (13.8) 10,208.33 10,179.65
2011 67.5 (10.7) 64 (12.9) 11,410.12 11,030.95
2004–2011 66.8 (10.9) 63.2 (13.3) 10,914.89 10,935.89
Malignant neoplasm of larynx
2004 62.7 (10.8) 57.4 (13.5) 12,888.20 12,290.71
2011 64.1 (10.6) 61.5 (12.6) 16,072.12 16,133.86
2004–2011 63.4 (10.8) 60 (12.8) 15,294.45 15,046.94
Malignant neoplasm of ovary
2004 — 61.5 (14.1) — 8,744.95
2011 — 61.3 (14.3) — 13,133.32
2004–2011 — 61.1 (14.3) — 10,086.77
Malignant neoplasm of colon
2004 69.5 (11.1) — 14,654.79 0.00
2011 70.4 (11.2) — 21,261.86 0.00
2004–2011 70.1 (11.2) — 18,199.75 0.00
Malignant neoplasm of rectum
2004 68.5 (11.2) — 13,138.08 0.00
2011 68.6 (11.6) — 19,667.39 0.00
2004–2011 68.6 (11.4) — 16,720.29 0.00
Source: prepared by the authors from data provided by Ministerio de 
Sanidad, Servicios Sociales e Igualdad (2013)16) and Table 5
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increase in specialist outpatient consultancies for ARDs 
from 178 in 2004 to 1,071 in 2011, which may be attrib-
utable to a trend for the outpatient rather than in-hospital 
treatment of these diseases. It should be borne in mind that 
the coverage of the information system is complete for 
hospitalizations and for specialist outpatient surgery but is 
only 46.7% for the medical activity of the outpatient day 
hospital21). A further potential limitation is that our utiliza-
tion of ratios for the whole period as a proxy of primary, 
specialist, and pharmaceutical care costs assumes that 
there was no substantial variation in the treatment of these 
diseases between 2004 and 2011. This appears to be a rea-
sonable assumption, but a certain degree of bias cannot be 
ruled out.
There was an increase in consultancies for all ARDs 
with the exception of asbestosis, responsible for the small-
est number of consultancies, which rose until 2006 and 
then declined, consistent with published evidence on the 
decline in the morbidity and mortality of this disease in 
Spain and Europe10, 20).
Previous studies on the attribution of ARDs to occu-
pational exposure concluded that this approach is highly 
unlikely to overestimate the true impact of this exposure 
on morbidity and mortality22 – 24). In fact, as noted above, 
our data likely represent an underestimation, because no 
account was taken of pharyngeal or stomach cancers, as the 
proportion due to asbestos exposure has not yet been eluci-
dated. The WHO concluded that occupational exposure to 
asbestos remains a major cause of death and disability in 
Europe, despite the conservative assumptions that under-
lie published estimates12). All studies have found that more 
than half of occupational cancers involve the lung, and that 
asbestos is the main occupational carcinogen25).
We calculated the direct costs to the NHS of the diag-
nosis and treatment of the disease but took no account of 
indirect costs, such as the loss of productivity caused by 
the temporary/permanent disability and premature death of 
workers or the cost of carers, etc. Even though our estimate 
of the total costs generated by these conditions is there-
fore at the lower end, it indicates an expenditure of more 
than 463 million euros between 2004 and 2011 (51 in 2004 
and 65 in 2011), with a mean annual increase of 3.5%. It 
has been reported that 66%–85% of the total health costs 
of cancer are indirect costs, including sick leave and early 
retirement, and especially the cost of mortality in people 
of working age12, 26 – 28). Evaluation of the full economic 
impact of ARDs in Spain requires an assessment of the 
indirect costs and their addition to the direct costs calcu-
lated in the present study.
The greatest proportion of direct healthcare costs were 
for specialist care services (around 51%), followed by 
pharmaceutical prescriptions (39%). It was previously 
reported that 50% of the cost of cancer in Spain was for 
the hospitalization of patients, and that 15% was for phar-
macologic treatments. Over the period from 2004 through 
2011, there was no difference in the time course of costs 
among the components of specialist care with the excep-
tion of day hospital costs, which showed a mean annual 
increase of more than 100% (10-fold higher in 2011 than 
in 2004), whereas the average annual increase in hospital-
ization was only 2.9%.
Comparison of our findings is hampered by the different 
methods used in research on medical costs as a function of 
the specific objectives and resources available, as affirmed 
at the WHO meeting in Bonn in 201212). The annual global 
cost of medical treatment for ARDs has been estimated at 
4.34 billion USD29). At the aforementioned WHO meeting 
in Bonn, it was stated that the mean acute treatment cost 
per case of mesothelioma was 15,899.34 € in the United 
Kingdom12), compared with previous estimates of 15,000 
€ in Scotland in 200630), 24,000 € in Italy in 201119), and 
20,218 € for males in 2011 (present study). Lifetime 
healthcare costs of pleural mesothelioma in Taiwan were 
estimated to be 14,900 USD in 1997 – 200531). An inves-
tigation of the direct healthcare sources of occupational 
lung and bladder cancers in Spain in 200824) estimated a 
cost per lung cancer patient of 9,277 €, lower than the cost 
of 11,566 € estimated in the present study. In Canada, the 
median cost per case in the 2000s of non-small cell lung 
cancer and small cell lung cancer were $10,928 (range 
$9,234 – 11,047) and $15,350 (range $13,033 – 21,436) 
respectively12). The aforementioned study on cancer costs 
in Spain found a cost of 19,535 € per case of colon can-
cer27), similar to the present finding although different 
computational methods were used.
Our calculation of the direct healthcare costs of occu-
pational ARDs in Spain should be considered the lower 
limit for the reasons noted above, but it is not possible to 
calculate the degree of underestimation from the infor-
mation available. The assumptions used to calculate the 
components of healthcare also represent a bias, especially 
with respect to the costs of prescriptions and primary care, 
whose estimation was derived from a geographic area 
that cannot be considered representative of the nation as 
a whole, given the variability in disease prevalence and in 
the offer of medical services among regions. Nevertheless, 
there can be no doubt about the high healthcare costs of 
ARDs in Spain, especially given the potentially prevent-
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able nature of these diseases. The elevated economic bur-
den of ARDs underlines the need to increase their preven-
tion and their early diagnosis and treatment.
As declared by the WHO European Region at its latest 
meeting12), asbestos continues to present a public health 
threat, despite bans on its import and use, due to wide expo-
sure in the past. The recognition, diagnosis, and recording 
of ARDs remain challenging. However, estimation of their 
costs is of particular importance at a time of economic 
pressures on the health service. The proper demarcation of 
financial responsibilities between the National Insurance 
System (including Work Accidents and Occupational Dis-
eases Insurance Institutes) and the National Health System 
is a highly relevant issue. Costs of occupational diseases 
should be funded by social contributions from employers 
and employees under the National Insurance System rather 
than by the tax-funded National Health System.
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